Thomas Van Blarcom
Overview
Explore the profile of Thomas Van Blarcom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dingfelder J, Taubmann J, von Heydebrand F, Aigner M, Bergmann C, Knitza J, et al.
Int J Mol Sci
. 2025 Jan;
26(2).
PMID: 39859183
Systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myositis (IIM) are autoimmune diseases managed with long-term immunosuppressive therapies. Hu19-CD828Z, a fully human anti-CD19 chimeric antigen receptor (CAR) with...
2.
Zhang Y, Tacheva-Grigorova S, Sutton J, Melton Z, Mak Y, Lay C, et al.
Clin Cancer Res
. 2023 Jan;
29(5):971-985.
PMID: 36692420
Purpose: Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options. Delta-like ligand 3 (DLL3) is highly expressed on SCLC and several other types of neuroendocrine cancers,...
3.
Panowski S, Srinivasan S, Tan N, Tacheva-Grigorova S, Smith B, Mak Y, et al.
Cancer Res
. 2022 Mar;
82(14):2610-2624.
PMID: 35294525
Significance: These findings demonstrate the efficacy and safety of fratricide-resistant, allogeneic anti-CD70 CAR T cells targeting renal cell carcinoma and the impact of CAR epitope on functional activity. See related...
4.
Chen S, Dominik P, Stanfield J, Ding S, Yang W, Kurd N, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34599020
Background: T cell checkpoint immunotherapies have shown promising results in the clinic, but most patients remain non-responsive. CD47-signal regulatory protein alpha (SIRPα) myeloid checkpoint blockade has shown early clinical activity...
5.
Zhu G, Foletti D, Liu X, Ding S, Witt J, Hasa-Moreno A, et al.
Sci Rep
. 2019 Nov;
9(1):16735.
PMID: 31700121
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
6.
Zhu G, Foletti D, Liu X, Ding S, Witt J, Hasa-Moreno A, et al.
Sci Rep
. 2019 Jun;
9(1):8420.
PMID: 31182754
Human CLDN18.2 is highly expressed in a significant proportion of gastric and pancreatic adenocarcinomas, while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes...
7.
Sommer C, Boldajipour B, Kuo T, Bentley T, Sutton J, Chen A, et al.
Mol Ther
. 2019 Apr;
27(6):1126-1138.
PMID: 31005597
Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological...
8.
Van Blarcom T, Rossi A, Foletti D, Sundar P, Pitts S, Melton Z, et al.
Methods Mol Biol
. 2018 May;
1785:89-118.
PMID: 29714014
Monoclonal antibodies are the largest class of therapeutic proteins due in part to their ability to bind an antigen with a high degree of affinity and specificity. A precise determination...
9.
Toomey C, Landowski M, Klingeborn M, Kelly U, Deans J, Dong H, et al.
Invest Ophthalmol Vis Sci
. 2018 Feb;
59(2):662-673.
PMID: 29392311
Purpose: A large body of evidence supports a central role for complement activation in the pathobiology of age-related macular degeneration (AMD), including plasma complement component 5a (C5a). Interestingly, C5a is...
10.
Van Blarcom T, Lindquist K, Melton Z, Cheung W, Wagstrom C, McDonough D, et al.
MAbs
. 2017 Dec;
10(2):256-268.
PMID: 29227213
The commercial success of bispecific antibodies generally has been hindered by the complexities associated with generating appropriate molecules for both research scale and large scale manufacturing purposes. Bispecific IgG (BsIgG)...